Publicaciones en colaboración con investigadores/as de Copenhagen University Hospital (1)

2013

  1. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): An open-label randomised study

    The Lancet Oncology, Vol. 14, Núm. 10, pp. 962-970